Celgene Corporation today announced that information was posted on the FDA Web site indicating that an Abbreviated New Drug Application (ANDA) has been received by the Office of Generic Drugs (OGD) containing a "Paragraph IV" patent certification, for REVLIMID (lenalidomide) 25 mg capsules. Celgene has not yet received the Paragraph IV notification letter identifying the filer.

SHIRE PLC - Shire Receives Paragraph IV Notice Letter Trading Markets (press release) ... but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit Hyperactivity Disorder ("ADHD")); ... and more »

DUBLIN, May 28, 2010 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has received a Paragraph IV Notice Letter today from Zydus Pharmaceuticals USA, Inc. ("Zydus") advising of the filing of an Abbreviated New Drug Application ("ANDA") for a generic version of Shire's 1.2g mesalamine delayed release tablets, LIALDA(R).

Shire Receives LIALDA(R) Paragraph IV Notice Letter From Zydus Pharmaceuticals Trading Markets (press release) ... but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit Hyperactivity Disorder ("ADHD")); ... and more »

(Corrects Adderall sales in third paragraph.) April 29 (Bloomberg) -- Shire Plc said first-quarter profit fell 22 percent as a flood of generic competition to the drugmaker’s Adderall XR hyperactivity pill eroded sales.